Xiyou Liu
Hubei Cancer Hospital(CN)Huazhong University of Science and Technology(CN)
Publications by Year
Research Areas
DNA Repair Mechanisms, Corporate Finance and Governance, Cancer-related Molecular Pathways, PARP inhibition in cancer therapy, Auditing, Earnings Management, Governance
Most-Cited Works
- → Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy(2019)56 cited
- → Reduced graphene oxide supported titanium dioxide nanomaterials for the photocatalysis with long cycling life(2015)29 cited
- → BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer(2017)28 cited
- → Association of 15-hydroxyprostaglandin dehydrogenate and poor prognosis of obese breast cancer patients(2017)12 cited
- → <p>ASAP3 is a downstream target of HIF-1α and is critical for progression of lung adenocarcinoma</p>(2019)7 cited
- → Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma(2020)7 cited
- → Post-radiotherapy maintenance treatment with fluticasone propionate and salmeterol for lung cancer patients with grade III radiation pneumonitis(2018)6 cited
- The Voluntary Adoption of an Audit Committee and Earnings Quality: Evidence from China(2012)
- → Data from BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer(2023)
- → Supplementary figure, tables and information from BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer(2023)